MitraClip China PMS
Key facts
- Who runs it
- Abbott Medical Devices
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 51 people enrolled
- Started
- 6 Dec 2021
- Ended
- 7 Mar 2025
- Type of study
- Interventional
- Treatments tested
- MitraClip procedure
- Record updated
- 15 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Subjects is eligible to receive the MitraClip per the current approved MitraClip System IFU. (If any update or amendment on the IFU, the latest version of IFU shall be followed.)
- Subject is 18 years-old or above
- Subjects who give consent for study procedure
Who cannot take part
- Subject is unlikely to survive the protocol follow up period of 12-months after device implant
- Subject with rheumatic mitral valve disease
- Subject cannot tolerate procedural anticoagulation or anti-platelet regimen
- Subject with active endocarditis of mitral valve
- Subject with echocardiographic evidence of intracardiac, IVC or femoral venous thrombus
- Subject has insufficient or lost ability to maintain their will and rights
- Subject is illiterate
- Pregnant or nursing subjects and those who plan pregnancy during the study follow-up period
- Subject participates in another clinical study that may impact the follow-up or results of this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The MitraClip System is the first commercially available catheter-based option for the treatment of MR. The MitraClip System was developed as an alternate percutaneous technology which may serve as a viable therapeutic option for open-heart surgery. Treatment with the MitraClip device allows patients to undergo a less invasive procedure that can mechanistically reduce MR and allow for improved quality of life. The MitraClip procedure is performed under general anesthesia without the use of a heart-lung machine, with recovery typically lasting two to three days.
The group in the trial
- MitraClipTreatment being tested
Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.
Treatment: MitraClip procedure
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-Center, Single-Arm, Post Market Study of the MitraClip System for the Treatment of Symptomatic Mitral Regurgitation in China
- Record updated
- 15 December 2025